LYRA Lyra Therapeutics Inc: Enterprise Value to EBITDA Ratio

lyratherapeutics.com (LYRA) - corporate logo

Lyra Therapeutics, Inc. (LYRA) generates revenue by developing advanced implants for the therapy of ENT diseases, offering clinics an alternative to complex surgeries. The business's success relies on the precision of drug delivery systems in the nasopharynx and the expansion of insurance limits. The price action based on the EV/EBITDA multiple, which currently stands at 0.00, highlights a period of aggressive asset restructuring and a strategic pivot following the failure of several clinical trials.

Lyra Therapeutics Inc. - LYRA Business Value to Operating Income Before Depreciation (period 11/23/2025 - 03/28/2026)

Comprehensive metric breakdowns and analytics for Lyra Therapeutics Inc. (LYRA)

- market price and analyst price targets:
Summary company analytics:Lyra Therapeutics Inc. (LYRA)
Original product of Lyra Therapeutics

For an investor, assessing the sustainability of Lyra Therapeutics, Inc. (LYRA) requires analyzing the company's ability to cover capital expenditures for biomaterials science and clinical trials through operating profit. This enterprise value-to-EBITDA ratio allows for the determination of the business's real market price accounting for debt and excluding depreciation, which is critical for research-intensive pharma with high investments in implant development.

Competitor analysis

Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Enterprise Value to Operating Income Before Depreciation|China SXT Pharmaceuticals - Enterprise Value to EBITDA Ratio|EPRX: Enterprise Value to Operating Income Before Depreciation|BHST: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Invizyne|Oramed Pharmaceuticals Inc. (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENTX (Entera Bio Ltd) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio HYFT|ABVC BioPharma, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen FGEN|EV/EBITDA Multiple telomirpharma.com TELO|Rani Therapeutics Inc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation SNYR (synergychc.com)|Rallybio (RLYB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Lexaria Bioscience Corp|Enterprise Value to EBITDA Ratio PULM|PTHL - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple APM|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio